Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients - Concepedia

Concepedia

Publication | Closed Access

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen‐allergic patients

62

Citations

26

References

2015

Year

Emmanuel Nony, Julien Bouley, Maxime Le Mignon, P. Lemoine, K. Jain, S. Horiot, Laurent Mascarell, Marc Pallardy, Renaud Vincentelli, Patrizia Leone,

Abstract

Recombinant Bet v 1 has been produced as a well-characterized pharmaceutical-grade biological drug. Sublingual administration of rBet v 1 tablets is safe and efficacious in patients with BP allergic rhinoconjunctivitis.

References

	Year	Citations

Page 1